LPCAT1在FAB-M2亚型成人急性髓系白血病患者中的预后意义  

Prognostic Significance of LPCAT1 in Adult Acute Myeloid Leukemia Patients with FAB Subtype M2

作　　者：刘宇[1] 刘雅筠 杨璐[1] 张雨 张丹凤 姜中兴[1] 王冲[1] 刘延方[1] 王树娟[1] LIU Yu;LIU Ya-Jun;YANG Lu;ZHANG Yu;ZHANG Dan-Feng;JIANG Zhong-Xing;WANG Chong;LIU Yan-Fang;WANG Shu-Juan(Department of Hematology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan Province,China;Department of Orthopaedics,Brown University,Warren Alpert Medical School/Rhode Island Hospital,Rhode Island,the United States,Providence,RI 02903)

机构地区：[1]郑州大学第一附属医院血液科,河南郑州450052 [2]Brown University,Warren Alpert Medical School/Rhode Island Hospital,Rhode Island,Providence,RI 02903

出　　处：《中国实验血液学杂志》2023年第1期64-70,共7页Journal of Experimental Hematology

基　　金：国家自然科学基金资助项目(81800137,U1804191)。

摘　　要：目的:研究溶血磷脂酰胆碱酰基转移酶1(LPCAT1)在急性髓系白血病(AML)中的预后价值。方法:使用基于Taq Man的逆转录-实时荧光定量聚合酶链反应检测214例初治成人AML患者和24例健康对照者LPCAT1的相对表达量。使用Kaplan-Meier方法进行生存分析,Cox比例风险回归模型用于确定预后因素。结果:LPCAT1在成人AML中的表达水平为34.37%(1.83%-392.63%),显著低于健康对照者的92.81%(2.60%-325.84%)(P<0.001)。本研究在具有完整临床信息和预后数据的171例非急性早幼粒细胞白血病患者中评估了LPCAT1的预后意义。生存分析结果表明,LPCAT1的表达水平对整个队列的预后没有显著影响。然而,在FAB-M2亚型(M2-AML)的AML患者中,低表达LPCAT1患者的2年无复发生存率为35.4%(95%CI:0.107-0.601),显著低于高表达LPCAT1患者的79.2%(95%CI:0.627-0.957)(P=0.012)。多因素分析结果表明,低表达LPCAT1是M2-AML患者无复发生存率的独立危险因素(HR=0.355,95%CI:0.126-0.966,P=0.049)。结论:LPCAT1在成人AML患者中低表达,LPCAT1低表达是M2-AML患者无复发生存率的独立危险因素。Objective:To study the prognostic value of LPCAT1 in acute myeloid leukemia (AML).Methods:Taq Man-based reverse transcription-quantitative polymerase chain reaction (RT-q PCR) was used to detect relative expression of LPCAT1 in 214 newly diagnosed adult AML patients and 24 normal controls.Survival functions were estimated using the Kaplan-Meier method and were compared by the Log-rank test.A Cox proportional hazard regression model was used to identify prognostic factors.Results:The expression level of LPCAT1 in adult AML was34.37%(1.83%-392.63%),which was significantly lower than 92.81%(2.60%-325.84%) of normal controls (P<0.001).The prognostic significance of LPCAT1 was evaluated in 171 non-acute promyelocytic leukemia patients with complete clinical information and prognostic data.Survival analysis showed that the expression level of LPCAT1 had no significant effect on the prognosis of the whole cohort.However,in AML patients with FAB subtype M2 (AML-M2),the 2-year relapse-free survival (RFS) rate of patients with low LPCAT1 expression was 35.4%(95%CI:0.107-0.601),which was significantly lower than 79.2%(95%CI:0.627-0.957) of patients with high LPCAT1 expression (P=0.012).Multivariate analysis showed that low expression of LPCAT1 was an independent risk factor for RFS of AML-M2 patients (HR=0.355,95%CI:0.126-0.966,P=0.049).Conclusion:In adult AML patients LPCAT1 shows low expression.Low LPCAT1expression is an independent risk factor for RFS in M2-AML patients.

关 键 词：急性髓系白血病 FAB-M2亚型 溶血磷脂酰胆碱酰基转移酶1 预后 

分 类 号：R733[医药卫生—肿瘤] R734.2[医药卫生—临床医学]